Express Report
Nomination for Advocacy Council
NGO Connect Program

Intellectual Property News

AG IP News
  • Forward Pharma Announces Completion of Corporate Restructuring Plan
    COPENHAGEN - Forward Pharma A/S announced in a press release the completion of its previously announced corporate restructuring plan (the “Restructuring”) substantially in the form set forth in Appendix D to the Settlement and License Agreement, dated January 17, 2017, by and among Forward Pharma, Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd. (collectively, “Biogen”) and certain other parties named therein (the “License Agreement”). The intellectual property of Forward Pharma that is the subject of the License Agreement (the “Licensed Intellectual Property”) has since June 30, 2017 been owned and controlled by FWP IP ApS, a Danish limited liability company, provided that Forward Pharma and Biogen continue to each have the authority to control the filing, prosecution, maintenance, defense and enforcement of specified Licensed Intellectual Property, in each case in accordance with the terms of, and to the extent such authority is granted to such party in, the License Agreement and restructuring agreements. The capital stock of FWP IP ApS has now been transferred to a newly formed Danish limited liability company, FWP HoldCo ApS, owned and controlled by a newly formed independent Danish foundation. The board of directors of the foundation and FWP HoldCo ApS consists of three members, comprised of one independent member and one member appointed by each of Forward Pharma and Biogen. All actions of the foundation and FWP HoldCo ApS require the unanimous approval of its board of directors. The foregoing summary of the Restructuring above does not purport to be complete and is subject to, and qualified in its entirety by, the full texts of the restructuring agreements, which were filed as exhibits to Forward Pharma’s semi-annual report for the period ended June 30, 2017. Forward Pharma shareholders are urged to read the restructuring agreements and the License Agreement in their entirety as well as other risk factors as outlined in the annual report for the year ended December 31, 2016, as filed under a form 20-F with the SEC.   
  • Prima Secures European Patent Grant
    SYDNEY - Prima BioMed Ltd announced in a press release the grant of patent number 2604275 entitled “Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response” by the European Patent Office. This European patent was filed as a divisional application and follows the grant of the European parent patent, which was issued in August 2013. The claims of this new patent are geared toward the use of Prima’s lead candidate IMP321 in combination with a chemotherapeutic agent for the treatment of cancer. According to the claims, IMP321 elicits a monocyte-mediated immune response and is administered before, with, or subsequent to administration of the chemotherapeutic agent. Importantly, these granted claims support the application of IMP321 in Prima’s AIPAC clinical trial in metastatic breast cancer in Europe. The patent expiry date is 3 October 2028.  
  • ICANN Community Onboarding Pilot Program Call for Nominations by SOs/ACs
    LOS ANGELES - ICANN has issued a call for nominations by the Supporting Organizations (SOs) and Advisory Committees (ACs) to the Community Onboarding Pilot (COP) Program for ICANN61. According to ICANN, the COP seeks to improve ICANN community newcomer engagement and retention rates through mentorship and knowledge and experience sharing. Nominations are due no later than December 15, 2017. ICANN's mission is to help ensure a stable, secure and unified global Internet. To reach another person on the Internet, you need to type an address – a name or a number – into your computer or other device. That address must be unique so computers know where to find each other. ICANN helps coordinate and support these unique identifiers across the world. ICANN was formed in 1998 as a not-for-profit public-benefit corporation with a community of participants from all over the world.  

My Caring Brands

Brands and Fakes has aligned the capabilities of the service delivery eco system with the industry verticals, so that the Brands under various industry verticals and sub verticals are able to get services from expertise in their specific domains.